|
Table 1: Baseline demographic and clinical data. |
|||
|
Total knee arthroplasty |
|||
|
Control group N = 80 n (%) |
Tranexamic acid group N = 68 n (%) |
p* |
|
|
Age‡ |
71.39 ± 8.74 |
69.98 ± 8.69 |
0.331 |
|
Sex |
|||
|
Male Female |
23 57 |
24 44 |
|
|
Non risk factor patients |
58 (72.5) |
51 (75) |
|
|
Previous VTE or anticoagulant |
22 (27.5) |
17 (25) |
|
|
Total hip arthroplasty |
|||
|
Control group N = 84 n (%) |
Tranexamic acid group N = 50 n (%) |
p* |
|
|
Age‡ |
62.91 ± 13.31 |
65.46 ± 13.61 |
0.290 |
|
Sex |
|||
|
Male Female |
29 55 |
23 27 |
|
|
Non risk factor patients |
70 (83.33) |
37 (74) |
|
|
Previous VTE or anticoagulant |
14 (16.66) |
13 (26) |
|
|
* Students t-test. ‡ Mean ± standard deviation. VTE = venous thromboembolism. |
|||